- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03570918
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Study Overview
Detailed Description
Eligible participants will be maintained on ART and receive either one infusion (Part 1) or multiple infusions of MGD014 (Part 2). Part 1 is a single ascending dose study with a 1+3 design for the first 2 dose cohorts, and a 3+3 design with staggered accrual for the 6 higher dose cohorts, with an aim of determining the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending doses up to either the Optimal Biologic Dose (OBD) or the maximum administered dose (MAD).
Part 2 is a multi-dose expansion cohort with MGD014 administered at the OBD, as determined in Part 1. In Part 2, additional assessments on the effects of MGD014 on HIV latent infection parameters will be evaluated.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability and willingness of participant to provide written informed consent.
- HIV-1 infection, documented by any FDA-approved rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
- On a potent, stable, continuous ART regimen for ≥ 24 months prior to Screening.
- Plasma HIV-1 RNA < 50 copies/mL at two time points in the previous 12 months prior to screening (one time point can be screening) and never ≥ 50 copies/mL on 2 consecutive time points in the last 24 months.
- Adequate organ function based on acceptable laboratory parameters.
Exclusion Criteria:
- Women of childbearing potential defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or menopause.
- History or other evidence of severe illness, immunodeficiency other than HIV, or any other condition that would make the potential participant unsuitable for study.
- History or other evidence of any condition or process for which signs or symptoms could be confused with reactions to MGD014.
- History of any HIV immunotherapy or HIV vaccine except for MGD014 within 12 months prior to screening.
- History of clinically significant cardiovascular disease, severe allergic reactions, malignancy (except non-melanoma skin cancer) within 5 years, seizure disorder within 2 years, organ/tissue transplant, autoimmune disease, unstable asthma, bleeding disorder.
- Evidence of active viral, or antifungal treatment within 7 days prior to the initiation of study drug
- Active, asymptomatic, or suspected COVID-19/SARS-CoV-2 infection.
- Active, untreated syphilis.
- Use of blood products, cytokine therapy, growth-stimulating factors, cytotoxic chemotherapy or investigational therapy within 90 days.
- Current use of the antivirals maraviroc and/or enfuvirtide.
- Any vaccination with exception of flu vaccine within 30 days of screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MGD014 0.1 micrograms/kilogram (mcg/kg)
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 0.3 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 1.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 3.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 10.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 30.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 100.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 300.0 mcg/kg
a single 2-hour infusion
|
HIV-1 x CD3 bispecific DART molecule
|
EXPERIMENTAL: MGD014 300.0 mcg/kg multiple doses
2-hour infusion every 2 weeks for 3 infusions
|
HIV-1 x CD3 bispecific DART molecule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emerging Adverse Events
Time Frame: up to 77 days
|
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.
|
up to 77 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC Inf: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity of MGD014
Time Frame: Study Day 0 to 42
|
AUCinf, area under the concentration-time curve from the time of dose extrapolated to time infinity and reflects total drug exposure
|
Study Day 0 to 42
|
Cmax: Maximum Plasma Concentration
Time Frame: Study Day 0
|
Cmax is the maximum (or peak) serum concentration of a drug in the body after the drug has been administered
|
Study Day 0
|
Tmax: Time to Maximum Concentration
Time Frame: Study Day 0
|
Tmax is the time it takes a drug to reach the maximum concentration
|
Study Day 0
|
Ctrough: Trough Level Concentration
Time Frame: Study Day 14
|
a trough level or trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered,
|
Study Day 14
|
Clearance
Time Frame: Study Day 0 to 42
|
Total body clearance of the drug from plasma of MGD014
|
Study Day 0 to 42
|
Vz: Terminal Phase Volume of Distribution of MGD014
Time Frame: Study Day 1, 2, 7, 14, 21, 28, and 42 (single infusion) and Study Day 1, 3, 14, 28, 42, and 77 (multiple infusions)
|
The ratio of the total quantity of drug in the body to drug plasma concentration during the elimination
|
Study Day 1, 2, 7, 14, 21, 28, and 42 (single infusion) and Study Day 1, 3, 14, 28, 42, and 77 (multiple infusions)
|
Terminal Half Life of MGD014
Time Frame: Study Day 0 to Study Day 42
|
The half-life is the amount of time required for 50% of the drug to be removed from the body
|
Study Day 0 to Study Day 42
|
Number of Participants That Developed Antidrug Antibodies to MGD014
Time Frame: Study Day 1, 14, 28 and 42 (single infusion) and Study Day 1, 14, 28 and 77 (multiple infusions)
|
Number of participants with antidrug antibodies to MGD014
|
Study Day 1, 14, 28 and 42 (single infusion) and Study Day 1, 14, 28 and 77 (multiple infusions)
|
Number of Participants With Increased Cytokine Levels
Time Frame: Study Day 1, 2 and 7 (single infusion) and Study Day 1, 3, 14 and 28 (multiple infusions)
|
Number of participants with increased cytokine levels from baseline after MGD014 administration.
This safety measure compares serum cytokine levels obtained prior to dosing with levels obtained after dosing.
Increased cytokines can be a measure of T-cell activation in response to MGD014 binding.
Cytokines analyzed included interferon-gamma, tumor necrosis factor-alpha, interleukin (IL)2, IL-5, IL-6, and IL-10.
|
Study Day 1, 2 and 7 (single infusion) and Study Day 1, 3, 14 and 28 (multiple infusions)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-MGD014-01
- 272201500032C-2-0-1 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
-
GeoVax, Inc.University of Alabama at Birmingham; AIDS Research Consortium of Atlanta; AIDS...CompletedHIV-1 InfectionUnited States
Clinical Trials on MGD014
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States